RT Book, Section
A1 DaSilva, Marcelo C.
A1 Sugarbaker, Paul
A1 Sugarbaker, David J.
A2 Sugarbaker, David J.
A2 Bueno, Raphael
A2 Colson, Yolonda L.
A2 Jaklitsch, Michael T.
A2 Krasna, Mark J.
A2 Mentzer, Steven J.
A2 Williams, Marcia
A2 Adams, Ann
SR Print(0)
ID 1105845474
T1 Intracavitary Hyperthermic Chemotherapy for Malignant Mesothelioma
T2 Adult Chest Surgery, 2e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 978-0-07-178189-3
LK accesssurgery.mhmedical.com/content.aspx?aid=1105845474
RD 2021/02/28
AB The  rising  incidence  of  malignant  mesothelioma  worldwide  has  intensified  the  search  for  treatment  strategies  to  extend  disease-free  survival.1  To  date,  the  best  survival  has  been  observed  in  patients  undergoing  multimodality  therapy  with  surgery,  either  extrapleural  pneumonectomy  (EPP)  or  pleurectomy/decortication  (P/D),  plus  chemotherapy  and/or  radiation  therapy.2–7  Seminal  work  at  the  Washington  Cancer  Center  and  Brigham  and  Women's  Hospital  led  to  the  development  of  innovative  surgical  techniques  to  accomplish  macroscopic  complete  resection,  along  with  intracavitary  lavage  with  hyperthermic  platinum-based  chemotherapy  for  local  control.  The  rationale  for  hyperthermic  intraoperative  thoracoabdominal  chemotherapy  has  been  previously  described,  with  particular  emphasis  on  malignant  peritoneal  mesothelioma.8  This  chapter  describes  the  thoracic  delivery  of  heated  intraoperative  chemotherapy  for  patients  with  malignant  pleural  mesothelioma  (MPM),  along  with  special  advice  on  perioperative  pitfalls  and  complications.